<DOC>
	<DOCNO>NCT00003232</DOCNO>
	<brief_summary>RATIONALE : Some drug use chemotherapy reduce pain experienced people cancer . Combining one drug may effective reduce cancer pain . It know whether receive combination chemotherapy clodronate effective receive combination chemotherapy without clodronate hormone refractory metastatic prostate cancer . PURPOSE : Randomized double-blinded phase III trial compare effectiveness combination chemotherapy use mitoxantrone plus prednisone without clodronate treating pain patient hormone refractory metastatic prostate cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Pain Patients With Hormone Refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effect mitoxantrone prednisone without clodronate localize bone pain patient hormone refractory metastatic prostate cancer . II . Compare overall survival quality life patient treatment . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify accord quality pain ( mild v moderate ) previous corticosteroid one regimen non-anthracycline-containing cytotoxic chemotherapy ( e.g. , estramustine ) v none . Patients assign 1 2 treatment arm . Arm I consist oral prednisone twice day intravenous mitoxantrone follow intravenous clodronate administer 3 hour every 3 week . Arm II consist oral prednisone twice day intravenous mitoxantrone follow intravenous placebo administer 3 hour every 3 week . Doses adjust myelosuppression . Treatment continue disease progression ( although patient initially placebo continue open-label clodronate ) maximum cumulative dose mitoxantrone reach . Patients palliative response may continue prednisone study drug ( clodronate placebo ) disease progression . Quality life assess every 3 week study treatment . A daily pain diary also maintain . All patient follow 2 week every 3 month death . PROJECTED ACCRUAL : This study accrue 204 patient .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Clodronic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate metastatic carcinoma presumptive prostate origin manifest presence sclerotic bony metastasis serum PSA level great upper limit normal Radiologically proven progressive bone disease ( e.g. , new bone scan lesion , increase uptake isotope previous site disease , and/or increase bone pain ) Hormone refractory disease ( i.e. , disease progression recurrence despite documented castrate level serum testosterone achieve bilateral orchiectomy antiandrogen therapy ) Bone pain due metastatic disease Patients must achieve stable analgesia least 7 day No uncontrolled epidural metastasis PATIENT CHARACTERISTICS : Age : Any age Performance status : ECOG 03 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Absolute granulocyte count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 3.15 mg/dL Renal : Creatinine le 2.26 mg/dL Serum calcium great 3.1 mmol/L Cardiovascular : Patients history angina pectoris , previous cardiac infarction , hypertension , valvular congenital heart disease must baseline measurement LVEF exceed 50 % Other : No malignancy within 5 year except nonmelanomatous skin cancer No active infection contraindication chemotherapy mitoxantrone No spinal cord nerve root compression No unstabilized impend pathological fracture PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : One previous course chemotherapy allow No prior mitoxantrone anthracycline Endocrine therapy : See Disease Characteristics At least 4 week since prior nonsteroidal antiandrogens Radiotherapy : At least 4 week since prior radiotherapy At least 8 week since prior strontium89 samarium153 Surgery : Not specify Other : No prior bisphosphonate therapy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>pain</keyword>
	<keyword>quality life</keyword>
</DOC>